Controls Getein Biotech provides Controls Solution on Getein platforms, covering multiples fields including cardiovascular diseases, inflammation, kidney injury, diabetes mellitus, fertility, etc
Following GLP-1 deprescription, patients weight did not significantly increase at 6 or 12 months post deprescription, compared to many well-known drug trials (in red) where patients regain up to two thirds of weight loss after discontinuing the drug
Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage
These results indicate that Tirzepatide vs Semaglutide weight loss comparisons may favor Tirzepatide may offer superior body weight reduction benefits compared to Semaglutide
(2021) 46:E35868
Made in Canada: Produced in a quality-controlled facility